Navigation Links
Targeted agent shows promise in biliary cancer study
Date:4/20/2009

COLUMBUS, Ohio An experimental agent has shown promising results in people with advanced biliary cancer, according to a multi-institutional clinical trial led by cancer researchers at the Ohio State University.

The agent, known as AZD6244 (ARRY-142886), blocks certain enzymes that cancer cells need to proliferate and survive.

About 100,000 patients are diagnosed with biliary cancer worldwide every year, representing 15-20 percent of all liver cancer cases. Most patients present at later stages of the disease, which has a universally poor outcome.

The findings of the 28-patient, phase II study will be reported April 20 at the annual meeting of the American Association for Cancer Research in Denver, Colorado.

"This is a malignancy for which there is no standard of care," says the study's principal investigator Dr. Tanios Bekaii-Saab, assistant professor of medicine and pharmacology, and a medical oncologist who specializes in gastrointestinal cancers at Ohio State's Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute.

"And while it is a small study, it provides a strong rational for developing this agent further in larger trials either alone or in combination with other drugs, with the hope that we can establish a new standard of care for biliary cancers in the near future."

Bekaii-Saab noted that the average progression-free survival achieved by patients in the study was one of the highest reported in the literature for this malignancy with many patients gaining weight in a disease that is typically associated with significant weight loss. The drug, which is administered orally, seems to be well tolerated with mild toxicities.

The agent belongs to a class of drugs called protein kinase inhibitors. This particular drug targets a protein kinase called MEK 1/2, which is part of a chemical pathway that is often damaged in many biliary cancer cases, Bekaii-Saab says.

In add
'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted Treatments Show Mettle Against Advanced Cancers
2. UCSF, Stanford Study Reveals Neural Networks Targeted in Brain Diseases
3. Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign
4. M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments
5. Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development
6. Pearly Penile Papule Patients Can Successfully Be Treated with Targeted CO2 Technology at La Jolla Cosmetic Surgery Centre
7. Targeted nanospheres find, penetrate, then fuel burning of melanoma
8. Health Integrated Achieves NCQA Full Accreditation for Its Synergy Targeted Population Management(TM) Program
9. Targeted Prostate Cancer Biopsy and Cancer Treatment Earns Acceptance From Nations Top Prostate Specialists
10. Anthem Blue Cross and Blue Shield Introduces SmartSense, Price-Conscious Plans Targeted at the Uninsured
11. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... The Triumph Modular, ... practices, consumer education, resource library, floor plans, educational blog and wide use of ... offers regular posts with valuable links to useful reports by industry experts. Comments ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... announces the Lost and Found, a breakthrough technological invention. It is a ... for the consumer electronic industry reached a record high of $211.3 billion in ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Morristown Medical Center, ... Jersey, and one of the first five hospitals in the nation, to implant the ... patients on July 23, and all are in good condition. , The CoreValve® Evolut® ...
(Date:7/28/2015)... ... July 28, 2015 , ... DuPont leaders today ... Ethiopia to learn more about the impact of U.S. collaborations with local partners ... on accelerating agricultural development as an engine of broad-based economic growth in the ...
(Date:7/28/2015)... ... 2015 , ... Women in Technology (WIT), the premier organization contributing to the ... has selected Lisa Dezzutti, CEO and president at Market Connections, Inc. as the organization’s ... this organization that empowers women to thrive and excel in the technology field. In ...
Breaking Medicine News(10 mins):Health News:Triumph Modular Launches Refreshed Modular Building Industry Website 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 4Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 5Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 4Health News:Lisa Dezzutti Named President of Women in Technology (WIT) Board of Directors 2
... , VANCOUVER, June 10 /PRNewswire-FirstCall/ - Response Biomedical Corporation ... Livleen Kaler has been appointed Vice President Finance & ... years of financial management experience in several industries. , ... the Board is pleased to recognize Livleen for her ...
... Trust Inc. (NYSE: CRE ) ("Care" or the ... dividend of $0.17 per share of common stock for the first ... to common shareholders of record on June 23, 2009. , ... Trust Inc. is a real estate investment and finance company investing ...
... One of Bucks County,s largest employers will create more than ... the help of a new state investment in an ongoing ... an $11.1 million grant, on behalf of the Doylestown Hospital, ... , , The funds will be used ...
... statement from the American Chemistry Council regarding papers ... including: "Bisphenol-A Exposure In Utero Leads to Epigenetic ... "Low-Dose Bisphenol A Promotes Arrhythmogenesis in the Female ... Belcher, PhD; and "Oral Exposure of Female Rhesus ...
... find similar results , WEDNESDAY, June 10 (HealthDay News) ... drugs after radiation therapy do better when the drug treatment ... six-month regimen, a European study has found. , The results ... in May, said Dr. Eric M. Horwitz, acting chairman of ...
... Metoclopramide, a drug approved in the U.S. for nausea, ... according to a large cohort study published in the June ... Medicine , "The Safety of Metoclopramide Use in the First ... June 11, 2009). According to the pediatrician and clinical ...
Cached Medicine News:Health News:Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer 2Health News:Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer 3Health News:Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer 4Health News:Care Investment Trust Inc. Announces Quarterly Dividend 2Health News:State to Invest $11.1 Million in Expansion of Doylestown Hospital 2Health News:Press Releases on BPA Studies By-Pass Scientific Process 2Health News:Longer Hormone Treatment May Improve Prostate Cancer Outlook 2Health News:Longer Hormone Treatment May Improve Prostate Cancer Outlook 3Health News:Off-label morning sickness drug deemed safe for fetuses -- Ben-Gurion U. researchers 2
(Date:7/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cng4gn/refurbished ) has announced the ... Global Forecasts to 2019" report to their offering. ... estimated to grow expected to reach $9.37 billion by ... 2019. Factors such as growing ... increasing privatization in the healthcare sector, and rising adoption ...
(Date:7/28/2015)... 28, 2015  PD-Rx Pharmaceuticals, Inc., a publicly ... has partnered with Dobson Technologies, a fully-integrated outsourced ... (IaaS) product. PD-Rx is an Application ... United States.  Using Dobson Technologies, IaaS solution will ... continuity, ensure regulatory compliance, and reduce operating expenses.  ...
(Date:7/28/2015)... , July 28, 2015  For many medical ... researchers, physicians and other inventors can be a constant ... is difficult, and successes are rare. A ... to change that. Medical Device Investments (MDI) ... from universities, hospitals and physicians. MDI develops, manufactures and ...
Breaking Medicine Technology:Refurbished Medical Equipment Market 2015 - Global Forecasts to 2019 2PD-Rx Partners With Dobson Technologies 2Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2
... and TARRYTOWN, N.Y., Nov. 10, 2011 Sanofi ... and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ... Phase 2 study program in which patients with ... REGN727/SAR236553. REGN727/SAR236553 is a novel, high-affinity, ...
... NASHVILLE, Tenn., Nov. 9, 2011 Revenue ... Non-GAAP Adjusted EBITDA of $76.7 million, increased 15.3% over third ... of healthcare revenue and payment cycle management and clinical information ... ended September 30, 2011, as summarized below: (In millions, except ...
Cached Medicine Technology:Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 2Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 3Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 4Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 5Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 6Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 7Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 8Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia 9Emdeon Reports Third Quarter 2011 Results 2Emdeon Reports Third Quarter 2011 Results 3Emdeon Reports Third Quarter 2011 Results 4Emdeon Reports Third Quarter 2011 Results 5Emdeon Reports Third Quarter 2011 Results 6Emdeon Reports Third Quarter 2011 Results 7Emdeon Reports Third Quarter 2011 Results 8Emdeon Reports Third Quarter 2011 Results 9Emdeon Reports Third Quarter 2011 Results 10Emdeon Reports Third Quarter 2011 Results 11Emdeon Reports Third Quarter 2011 Results 12Emdeon Reports Third Quarter 2011 Results 13
... of a Matching Card, three HRR symbol cards ... a child for subsequent HRR 4th Edition color ... test. For the youngest patients, the parents can ... the concept of matching and become familiar with ...
Magnetic Farnsworth D15 kit. Magnets move the color disks. Protects disks from fingerprints. Keeps all the disks in one place. Clear glass insures accurate color perception. Makes color testing fun....
... test from Richmond Products includes the four demonstration ... diagnostic series for a total of 24 plates. ... for easy and clean page selection. The test ... and a laminated copy of the score sheet. ...
Ishihara 14 plate color vision testing set. Suitable for screening purposes....
Medicine Products: